Literature DB >> 12980832

Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. I. Plan of controlled field tests and results of 1951 pilot study in Utah.

W M HAMMON, L L CORIELL, J STOKES.   

Abstract

Entities:  

Keywords:  POLIOMYELITIS/prevention and control; SERUM GLOBULIN/therapeutic use

Mesh:

Substances:

Year:  1952        PMID: 12980832     DOI: 10.1001/jama.1952.03680080001001

Source DB:  PubMed          Journal:  J Am Med Assoc        ISSN: 0002-9955


× No keyword cloud information.
  14 in total

1.  [Behavior of intramuscular, intravenous and oral gamma globulin].

Authors:  R MARTIN DU PAN; J J SCHEIDEGGER; P WENGER; B KOECHLI; J ROUX
Journal:  Blut       Date:  1959-04

2.  Approach to control of poliomyelitis by immunological methods.

Authors:  T FRANCIS
Journal:  Bull N Y Acad Med       Date:  1955-04

3.  The epidemiology of poliomyelitis; a study of an outbreak in Payson, Utah, 1951.

Authors:  P F WEHRLE
Journal:  Calif Med       Date:  1955-04

4.  Poliomyelitis vaccine in the fall of 1955.

Authors:  J E SALK
Journal:  Am J Public Health Nations Health       Date:  1956-01

5.  [Prevention of poliomyelitis; present and future].

Authors:  P LEPINE
Journal:  Bull World Health Organ       Date:  1955       Impact factor: 9.408

6.  [Virus diseases in otorhinolaryngology region].

Authors:  R HAAS
Journal:  Arch Ohren Nasen Kehlkopfheilkd       Date:  1955-05-02

7.  Immunization against poliomyelitis.

Authors:  T E BOYD
Journal:  Bacteriol Rev       Date:  1953-12

8.  Poliomyelitis distribution in the United States.

Authors:  R E SERFLING; I L SHERMAN
Journal:  Public Health Rep       Date:  1953-05       Impact factor: 2.792

9.  Clinical implications of plasma fractionation.

Authors:  I H SCHEINBERG
Journal:  Bull N Y Acad Med       Date:  1954-10

10.  A single chimpanzee-human neutralizing monoclonal antibody provides post-exposure protection against type 1 and type 2 polioviruses.

Authors:  Diana Kouiavskaia; Zhaochun Chen; Eugenia Dragunsky; Olga Mirochnitchenko; Robert Purcell; Konstantin Chumakov
Journal:  J Clin Virol       Date:  2015-02-03       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.